{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:59:28Z","timestamp":1792828768213,"version":"4.5.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The University of Osaka"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Theranostics, a novel integrated approach that combines cancer diagnosis and therapy by switching the radionuclide, has attracted growing attention. Various oncology PET probes other than FDG have been developed for the highly sensitive and precise detection of many types of cancer with the advancements in PET scanners, supporting the innovative development in theranostics. In therapeutic applications, radioligand therapy targeting somatostatin receptors (SSTR) and prostate-specific membrane antigen (PSMA) has already demonstrated significant clinical benefits. Terbium-161 (<jats:sup>161<\/jats:sup>Tb) has emerged as a new beta and Auger electron emitter, showing greater therapeutic efficacy compared to <jats:sup>177<\/jats:sup>Lu. Alpha emitters, such as astatine (<jats:sup>211<\/jats:sup>At), are currently being evaluated in investigator-initiated clinical trials, with preliminary efficacy data reported for [<jats:sup>211<\/jats:sup>At]NaAt in patients with radioiodine-refractory thyroid cancer. Novel pan-tumor targeting agents, such as TROP-2, Nectin-4, LAT1, GPC-1, and EphA2, are also under development, and clinical translation of radioligand therapy is anticipated. These innovations in theranostics are expected to further broaden the scope of precision medicine in oncology.<\/jats:p>","DOI":"10.1007\/s12149-025-02090-z","type":"journal-article","created":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T17:58:58Z","timestamp":1753639138000},"page":"909-921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Recent advances in theranostics and oncology PET: emerging radionuclides and targets"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-2395","authenticated-orcid":false,"given":"Tadashi","family":"Watabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Iima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yanagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Saida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rintaro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seitaro","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Sofue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiju","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Naganawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,27]]},"reference":[{"key":"2090_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.123.265670","volume":"64","author":"WA Weber","year":"2023","unstructured":"Weber WA, Barthel H, Bengel F, Eiber M, Herrmann K, Sch\u00e4fers M. What Is Theranostics? J Nucl Med. 2023;64:669\u201370.","journal-title":"J Nucl Med"},{"key":"2090_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2967\/jnumed.124.269215","volume":"66","author":"A Al-Ibraheem","year":"2025","unstructured":"Al-Ibraheem A, Scott AM, Abdlkadir AS, Vrachimis A, Lamoureux F, Trujillo PB, et al. Consensus nomenclature for radionuclide therapy: initial recommendations from nuclear medicine global initiative. J Nucl Med. 2025;66:757\u201363.","journal-title":"J Nucl Med"},{"key":"2090_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2967\/jnumed.122.265353","volume":"64","author":"B Feuerecker","year":"2023","unstructured":"Feuerecker B, Kratochwil C, Ahmadzadehfar H, Morgenstern A, Eiber M, Herrmann K, et al. Clinical translation of targeted \u03b1-therapy: an evolution or a revolution? J Nucl Med. 2023;64:685\u201392.","journal-title":"J Nucl Med"},{"key":"2090_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","volume":"23","author":"J Wei","year":"2024","unstructured":"Wei J, Li W, Zhang P, Guo F, Liu M. Current trends in sensitizing immune checkpoint inhibitors for cancer treatment. Mol Cancer. 2024;23:279.","journal-title":"Mol Cancer"},{"key":"2090_CR5","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamaoncol.2024.3456","volume":"10","author":"G Villacampa","year":"2024","unstructured":"Villacampa G, Navarro V, Matikas A, Ribeiro JM, Schettini F, Tolosa P, et al. Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2024;10:1331\u201341.","journal-title":"JAMA Oncol"},{"key":"2090_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","volume":"132","author":"B Jayathilaka","year":"2025","unstructured":"Jayathilaka B, Mian F, Franchini F, Au-Yeung G, IJzerman M,. Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review. Br J Cancer. 2025;132:51\u20137.","journal-title":"Br J Cancer"},{"key":"2090_CR7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s12149-023-01865-6","volume":"37","author":"K Hirata","year":"2023","unstructured":"Hirata K, Kamagata K, Ueda D, Yanagawa M, Kawamura M, Nakaura T, et al. From FDG and beyond: the evolving potential of nuclear medicine. Ann Nucl Med. 2023;37:583\u201395.","journal-title":"Ann Nucl Med"},{"key":"2090_CR8","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s12149-024-01981-x","volume":"38","author":"K Hirata","year":"2024","unstructured":"Hirata K, Matsui Y, Yamada A, Fujioka T, Yanagawa M, Nakaura T, et al. Generative AI and large language models in nuclear medicine: current status and future prospects. Ann Nucl Med. 2024;38:853\u201364.","journal-title":"Ann Nucl Med"},{"key":"2090_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11604-023-01507-x","volume":"42","author":"LF Shen","year":"2024","unstructured":"Shen LF, Fu ZM, Zhou SH. The role of radiotherapy in tumor immunity and the potential of PET\/CT in detecting the expression of PD-1\/PD-L1. Jpn J Radiol. 2024;42:347\u201353.","journal-title":"Jpn J Radiol"},{"key":"2090_CR10","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1007\/s00330-024-10651-5","volume":"34","author":"DJ Hughes","year":"2024","unstructured":"Hughes DJ, Josephides E, O\u2019Shea R, Manickavasagar T, Horst C, Hunter S, et al. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography\/computed tomography (PET\/CT) metabolic parameters in resectable non-small cell lung cancer. Eur Radiol. 2024;34:5889\u2013902.","journal-title":"Eur Radiol"},{"key":"2090_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11604-024-01554-y","volume":"42","author":"BM Gideonse","year":"2024","unstructured":"Gideonse BM, Birkeland M, Vilstrup MH, Grupe P, Naghavi-Behzad M, Ruhlmann CH, et al. Organ-specific accuracy of [18F]FDG-PET\/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor. Jpn J Radiol. 2024;42:753\u201364.","journal-title":"Jpn J Radiol"},{"issue":"supplement 1","key":"2090_CR12","volume":"66","author":"Y Wang","year":"2025","unstructured":"Wang Y, Liu Z, Hu M, Yu J. Can [18F]FDG-PET\/CT predict PD-L1 expression in head and neck carcinoma? a head-to-head comparison with a novel pd-l1 pet tracer. J Nucl Med. 2025;66(supplement 1): 251095.","journal-title":"J Nucl Med"},{"key":"2090_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s41824-024-00227-3","volume":"8","author":"C Gadens Zamboni","year":"2024","unstructured":"Gadens Zamboni C, Dundar A, Jain S, Kruzer M, Loeffler BT, Graves SA, et al. Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE\/[68Ga]Ga-DOTA-TOC PET\/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients. EJNMMI Rep. 2024;8:39.","journal-title":"EJNMMI Rep"},{"key":"2090_CR14","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2967\/jnumed.123.266262","volume":"65","author":"EMM Smeets","year":"2024","unstructured":"Smeets EMM, Trajkovic-Arsic M, Geijs D, Karakaya S, van Zanten M, Brosens LAA, et al. Histology-based radiomics for [18f]fdg pet identifies tissue heterogeneity in pancreatic cancer. J Nucl Med. 2024;65:1151\u20139.","journal-title":"J Nucl Med"},{"key":"2090_CR15","first-page":"312","volume":"41","author":"Q Li","year":"2023","unstructured":"Li Q, Li Y, Yuan H, Yang F, Huang Y, Song X, Jiang L. PET morphology helps distinguish solitary and solid pulmonary tuberculosis from non-small cell lung cancer. Jpn J Radiol. 2023;41:312\u201321.","journal-title":"Jpn J Radiol"},{"key":"2090_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11604-022-01347-1","volume":"41","author":"M Ni","year":"2023","unstructured":"Ni M, Wang S, Liu X, Shi Q, Zhu X, Zhang Y, et al. Predictive value of intratumor metabolic and heterogeneity parameters on [18F]FDG PET\/CT for EGFR mutations in patients with lung adenocarcinoma. Jpn J Radiol. 2023;41:209\u201318.","journal-title":"Jpn J Radiol"},{"key":"2090_CR17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s12149-024-01936-2","volume":"38","author":"KH Lue","year":"2024","unstructured":"Lue KH, Chen YH, Chu SC, Lin CB, Wang TF, Liu SH. Prognostic value of combining clinical factors, 18F-FDG PET-based intensity, volumetric features, and deep learning predictor in patients with EGFR-mutated lung adenocarcinoma undergoing targeted therapies: a cross-scanner and temporal validation study. Ann Nucl Med. 2024;38:647\u201358.","journal-title":"Ann Nucl Med"},{"key":"2090_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11604-022-01363-1","volume":"4","author":"W Wei","year":"2023","unstructured":"Wei W, Jia G, Wu Z, Wang T, Wang H, Wei K, Cheng C, Liu Z, Zuo C. A multidomain fusion model of radiomics and deep learning to discriminate between PDAC and AIP based on 18F-FDG PET\/CT images. Jpn J Radiol. 2023;4:417\u201327.","journal-title":"Jpn J Radiol"},{"key":"2090_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11604-023-01476-1","volume":"42","author":"M Nakajo","year":"2024","unstructured":"Nakajo M, Jinguji M, Ito S, Tani A, Hirahara M, Yoshiura T. Clinical application of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography radiomics-based machine learning analyses in the field of oncology. Jpn J Radiol. 2024;42:28\u201355.","journal-title":"Jpn J Radiol"},{"key":"2090_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11604-024-01649-6","volume":"43","author":"M Nakajo","year":"2025","unstructured":"Nakajo M, Hirahara D, Jinguji M, Hirahara M, Tani A, Nagano H, et al. Applying deep learning-based ensemble model to [18F]-FDG-PET-radiomic features for differentiating benign from malignant parotid gland diseases. Jpn J Radiol. 2025;43:91\u2013100.","journal-title":"Jpn J Radiol"},{"key":"2090_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s12149-024-01925-5","volume":"38","author":"C Sung","year":"2024","unstructured":"Sung C, Oh JS, Park BS, Kim SS, Song SY, Lee JJ. Diagnostic performance of a deep-learning model using 18F-FDG PET\/CT for evaluating recurrence after radiation therapy in patients with lung cancer. Ann Nucl Med. 2024;38:516\u201324.","journal-title":"Ann Nucl Med"},{"key":"2090_CR22","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s11604-023-01397-z","volume":"41","author":"M Nishimori","year":"2023","unstructured":"Nishimori M, Iwasa H, Nakaji K, Nitta N, Miyatake K, Yoshimatsu R, et al. Predicting the pathological invasiveness of early lung adenocarcinoma prior to surgery using Deauville criteria: reliability and validity. Jpn J Radiol. 2023;41:768\u201376.","journal-title":"Jpn J Radiol"},{"key":"2090_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s11604-022-01378-8","volume":"41","author":"H Iwasa","year":"2023","unstructured":"Iwasa H, Nagamachi S, Nakayama S, Yamamoto T, Yoshimitsu K. The reproducibility of MTV and TLG of soft tissue tumors calculated by FDG-PET: comparison between the lower limit by the fixed value SUV 2.5 and that value by 30% of SUVmax. Jpn J Radiol. 2023;41:531\u201340.","journal-title":"Jpn J Radiol"},{"key":"2090_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11604-024-01529-z","volume":"42","author":"Y Ueki","year":"2024","unstructured":"Ueki Y, Otsuka H, Otani T, Kasai R, Otomi Y, Ikemitsu D, et al. Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors. Jpn J Radiol. 2024;42:519\u201335.","journal-title":"Jpn J Radiol"},{"key":"2090_CR25","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s11604-023-01398-y","volume":"41","author":"Y Xie","year":"2023","unstructured":"Xie Y, Teng Y, Jiang C, Ding C, Zhou Z. Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL). Jpn J Radiol. 2023;41:777\u201386.","journal-title":"Jpn J Radiol"},{"key":"2090_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12149-024-01933-5","volume":"38","author":"WK Yap","year":"2024","unstructured":"Yap WK, Hsu KH, Wang TH, Lin CH, Kang CJ, Huang SM, et al. The prognostic value of lymph node to primary tumor standardized uptake value ratio in cancer patients: a meta-analysis. Ann Nucl Med. 2024;38:607\u201318.","journal-title":"Ann Nucl Med"},{"key":"2090_CR27","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s11604-024-01533-3","volume":"42","author":"H Kuroda","year":"2024","unstructured":"Kuroda H, Yoshizako T, Yada N, Kamimura T, Yamamoto N, Maruyama M, et al. Exploration of tumor size measurement methods in preoperative breast cancer assessment using whole-body silicon photomultiplier PET: feasibility and first results. Jpn J Radiol. 2024;42:639\u201347.","journal-title":"Jpn J Radiol"},{"key":"2090_CR28","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s12149-024-01964-y","volume":"38","author":"X Wumener","year":"2024","unstructured":"Wumener X, Zhang Y, Zang Z, Ye X, Zhao J, Zhao J, et al. The value of net influx constant based on FDG PET\/CT dynamic imaging in the differential diagnosis of metastatic from non-metastatic lymph nodes in lung cancer. Ann Nucl Med. 2024;38:904\u201312.","journal-title":"Ann Nucl Med"},{"key":"2090_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s12149-024-01922-8","volume":"38","author":"H Yin","year":"2024","unstructured":"Yin H, Liu G, Mao W, Lv J, Yu H, Cheng D, et al. Parametric net influx rate imaging of 68Ga-DOTATATE in patients with neuroendocrine tumors: assessment of lesion detectability. Ann Nucl Med. 2024;38:483\u201392.","journal-title":"Ann Nucl Med"},{"key":"2090_CR30","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s12149-023-01864-7","volume":"37","author":"LA Guner","year":"2023","unstructured":"Guner LA, Unal K, Beylergil V, Tuna MB, Saglican Y, Vardareli E, et al. Enhancing PSMA PET\/CT imaging of prostate cancer: investigating the impact of multiple time point evaluation, diuretic administration, cribriform pattern, and intraductal carcinoma. Ann Nucl Med. 2023;37:618\u201328.","journal-title":"Ann Nucl Med"},{"key":"2090_CR31","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s12149-024-01939-z","volume":"38","author":"P Burasothikul","year":"2024","unstructured":"Burasothikul P, Navikhacheevin C, Pasawang P, Sontrapornpol T, Sukprakun C, Khamwan K. Dual-time-point dynamic 68Ga-PSMA-11 PET\/CT for parametric imaging generation in prostate cancer. Ann Nucl Med. 2024;38:700\u201310.","journal-title":"Ann Nucl Med"},{"key":"2090_CR32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1053\/j.semnuclmed.2022.01.002","volume":"52","author":"QK Ng","year":"2022","unstructured":"Ng QK, Triumbari EKA, Omidvari N, Cherry SR, Badawi RD, Nardo L. Total-body PET\/CT - first clinical experiences and future perspectives. Semin Nucl Med. 2022;52:330\u20139.","journal-title":"Semin Nucl Med"},{"key":"2090_CR33","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s00259-024-06924-2","volume":"52","author":"Z Zheng","year":"2025","unstructured":"Zheng Z, He Y, Mao W, Yu H, Wu H, Yang R, et al. Exploration the feasibility and additional value of [18F]FDG\/[68Ga]Ga-FAPI-04 dual-low-activity-tracer one-stop total-body PET imaging at 34 min post-injection of [68Ga]Ga-FAPI-04. Eur J Nucl Med Mol Imaging. 2025;52:638\u201347.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2090_CR34","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.clon.2014.04.026","volume":"26","author":"GA Whitfield","year":"2014","unstructured":"Whitfield GA, Kennedy SR, Djoukhadar IK, Jackson A. Imaging and target volume delineation in glioma. Clin Oncol (R Coll Radiol). 2014;26:364\u201376.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2090_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41824-024-00189-6","volume":"8","author":"T Husby","year":"2024","unstructured":"Husby T, Johannessen K, Berntsen EM, Johansen H, Giske\u00f8deg\u00e5rd GF, Karlberg A, et al. 18F-FACBC and 18F-FDG PET\/MRI in the evaluation of 3 patients with primary central nervous system lymphoma: a pilot study. EJNMMI Rep. 2024;8:2.","journal-title":"EJNMMI Rep"},{"key":"2090_CR36","doi-asserted-by":"publisher","first-page":"522","DOI":"10.2967\/jnumed.121.262051","volume":"63","author":"C Brendle","year":"2022","unstructured":"Brendle C, Maier C, Bender B, Schittenhelm J, Paulsen F, Renovanz M, et al. Impact of 18F-FET PET\/MRI on clinical management of brain tumor patients. J Nucl Med. 2022;63:522\u20137.","journal-title":"J Nucl Med"},{"key":"2090_CR37","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s12149-024-01908-6","volume":"38","author":"K Kaneko","year":"2024","unstructured":"Kaneko K, Nagao M, Ueda K, Yamamoto A, Sakai S. Simultaneous evaluation of brain metastasis and thoracic cancer using semiconductor 11C-methionine PET\/CT imaging. Ann Nucl Med. 2024;38:278\u201387.","journal-title":"Ann Nucl Med"},{"key":"2090_CR38","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s11604-023-01450-x","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Fushimi Y, Arakawa Y, Shimizu Y, Sano K, Sakata A, et al. Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET. Jpn J Radiol. 2023;41:1255\u201364.","journal-title":"Jpn J Radiol"},{"key":"2090_CR39","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ijrobp.2023.10.014","volume":"118","author":"HK Perlow","year":"2024","unstructured":"Perlow HK, Nalin AP, Handley D, Gokun Y, Blakaj DM, Beyer SJ, et al. A prospective registry study of 68ga-dotatate PET\/CT incorporation into treatment planning of intracranial meningiomas. Int J Radiat Oncol Biol Phys. 2024;118:979\u201385.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2090_CR40","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2967\/jnumed.123.265486","volume":"64","author":"T Watabe","year":"2023","unstructured":"Watabe T, Naka S, Tatsumi M, Kamiya T, Kimura T, Shintani Y, et al. Initial evaluation of [18F]FAPI-74 PET for various histopathologically confirmed cancers and benign lesions. J Nucl Med. 2023;64:1225\u201331.","journal-title":"J Nucl Med"},{"issue":"8","key":"2090_CR41","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s12149-024-01935-3","volume":"38","author":"H Arak","year":"2024","unstructured":"Arak H, Elboga U, Cayirli YB, Aytekin A. Prognostic significance of\u00a068\u00a0Ga-FAPI PET\/CT in patients with bone metastases in various cancers. Ann Nucl Med. 2024;38(8):630\u20138. https:\/\/doi.org\/10.1007\/s12149-024-01935-3.","journal-title":"Ann Nucl Med"},{"key":"2090_CR42","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s11604-024-01528-0","volume":"42","author":"W Rao","year":"2024","unstructured":"Rao W, Fang XH, Zhao Y, Wang Y, Zhang B, Wei Z, et al. Clinical value of [18F]AlF-NOTA-FAPI-04 PET\/CT for assessing early-stage liver fibrosis in adult liver transplantation recipients compared with chronic HBV patients. Jpn J Radiol. 2024;42:536\u201345.","journal-title":"Jpn J Radiol"},{"key":"2090_CR43","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s12149-025-02027-6","volume":"39","author":"Y Mori","year":"2025","unstructured":"Mori Y, Tamburini K, Novruzov E, Schmitt D, Mavriopoulou E, Loosen SH, et al. Efficacy of [68Ga]Ga-FAPI-PET as a non-invasive evaluation method of liver fibrosis. Ann Nucl Med. 2025;39:631\u20139.","journal-title":"Ann Nucl Med"},{"key":"2090_CR44","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316.","journal-title":"Lancet"},{"key":"2090_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11604-024-01646-9","volume":"43","author":"T Otani","year":"2025","unstructured":"Otani T, Nakamoto R, Umeoka S, Nakamoto Y. PSMA PET\/CT imaging and its application to prostate cancer treatment. Jpn J Radiol. 2025;43:1\u201312.","journal-title":"Jpn J Radiol"},{"key":"2090_CR46","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s12149-021-01602-x","volume":"35","author":"T Watabe","year":"2021","unstructured":"Watabe T, Uemura M, Soeda F, Naka S, Ujike T, Hatano K, et al. High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients. Ann Nucl Med. 2021;35:523\u20138.","journal-title":"Ann Nucl Med"},{"key":"2090_CR47","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/jjco\/hyad166","volume":"54","author":"U Tateishi","year":"2024","unstructured":"Tateishi U, Kimura K, Tsuchiya J, Kano D, Watabe T, Nonomura N, et al. Phase I\/IIa trial of 18F-prostate specific membrane antigen (PSMA) 1007 PET\/CT in healthy volunteers and prostate cancer patients. Jpn J Clin Oncol. 2024;54:282\u201391.","journal-title":"Jpn J Clin Oncol"},{"key":"2090_CR48","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2967\/jnumed.122.264944","volume":"64","author":"J Cardinale","year":"2023","unstructured":"Cardinale J, Giesel FL, Wensky C, Rathke HG, Haberkorn U, Kratochwil C. PSMA-GCK01: a generator-based 99mTc\/188Re theranostic ligand for the prostate-specific membrane antigen. J Nucl Med. 2023;64:1069\u201375.","journal-title":"J Nucl Med"},{"key":"2090_CR49","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s12149-024-01959-9","volume":"38","author":"Y Shimizu","year":"2024","unstructured":"Shimizu Y, Ando M, Watanabe H, Ono M. Novel technetium-99m-labeled bivalent PSMA-targeting probe based on hydroxamamide chelate for diagnosis of prostate cancer. Ann Nucl Med. 2024;38:847\u201351.","journal-title":"Ann Nucl Med"},{"key":"2090_CR50","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.2967\/jnumed.124.268020","volume":"65","author":"F Pouliot","year":"2024","unstructured":"Pouliot F, Saad F, Rousseau E, Richard PO, Zamanian A, Probst S, et al. intrapatient intermetastatic heterogeneity determined by triple-tracer PET imaging in mCRPC patients and correlation to survival: the 3TMPO cohort study. J Nucl Med. 2024;65:1710\u20137.","journal-title":"J Nucl Med"},{"key":"2090_CR51","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s12149-024-01978-6","volume":"38","author":"G Belge Bilgin","year":"2024","unstructured":"Belge Bilgin G, Bilgin C, Orscelik A, Burkett BJ, Thorpe MP, Johnson DR, et al. Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis. Ann Nucl Med. 2024;38:865\u201376.","journal-title":"Ann Nucl Med"},{"key":"2090_CR52","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2967\/jnumed.120.247882","volume":"62","author":"GA Ulaner","year":"2021","unstructured":"Ulaner GA, Jhaveri K, Chandarlapaty S, Hatzoglou V, Riedl CC, Lewis JS, Mauguen A. Head-to-head evaluation of 18F-FES and 18F-FDG PET\/CT in metastatic invasive lobular breast cancer. J Nucl Med. 2021;62:326\u201331.","journal-title":"J Nucl Med"},{"key":"2090_CR53","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s12149-023-01871-8","volume":"37","author":"C Liu","year":"2023","unstructured":"Liu C, Ma G, Zhang J, Cheng J, Yang Z, Song S. 18F-FES and 18F-FDG PET\/CT imaging as a predictive biomarkers for metastatic breast cancer patients undergoing cyclin-dependent 4\/6 kinase inhibitors with endocrine treatment. Ann Nucl Med. 2023;37:675\u201384.","journal-title":"Ann Nucl Med"},{"key":"2090_CR54","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","volume":"128","author":"DL Chan","year":"2023","unstructured":"Chan DL, Hayes AR, Karfis I, Conner A, Furtado O\u2019Mahony L, Mileva M, et al. Dual [68Ga]DOTATATE and [18F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score. Br J Cancer. 2023;128:549\u201355.","journal-title":"Br J Cancer"},{"key":"2090_CR55","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752\u201363.","journal-title":"Lancet Oncol"},{"key":"2090_CR56","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317.","journal-title":"Lancet"},{"key":"2090_CR57","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12149-023-01899-w","volume":"38","author":"M Hotta","year":"2024","unstructured":"Hotta M, Sonni I, Thin P, Nguyen K, Gardner L, Ciuca L, et al. Visual and whole-body quantitative analyses of 68Ga-DOTATATE PET\/CT for prognosis of outcome after PRRT with 177Lu-DOTATATE. Ann Nucl Med. 2024;38:296\u2013304.","journal-title":"Ann Nucl Med"},{"key":"2090_CR58","doi-asserted-by":"publisher","first-page":"910","DOI":"10.2967\/jnumed.122.264964","volume":"64","author":"L Calderoni","year":"2023","unstructured":"Calderoni L, Maietti E, Farolfi A, Mei R, Louie KS, Groaning M, et al. Prostate-specific membrane antigen expression on PET\/CT in patients with metastatic castration-resistant prostate cancer: a retrospective observational study. J Nucl Med. 2023;64:910\u20137.","journal-title":"J Nucl Med"},{"key":"2090_CR59","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804.","journal-title":"Lancet"},{"key":"2090_CR60","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"2090_CR61","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404:1227\u201339.","journal-title":"Lancet"},{"key":"2090_CR62","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12149-023-01874-5","volume":"38","author":"K Michalski","year":"2024","unstructured":"Michalski K, Kosmala A, Werner RA, Serfling SE, Seitz AK, Lapa C, et al. Comparison of PET\/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy. Ann Nucl Med. 2024;38:87\u201395.","journal-title":"Ann Nucl Med"},{"key":"2090_CR63","first-page":"44","volume":"50","author":"T Higuchi","year":"2025","unstructured":"Higuchi T, Klimek K, Groener D, Chen X, Werner RA. Norepinephrine transporter-targeted cancer theranostics-new horizons. Clin Nucl Med. 2025;50:44\u201351.","journal-title":"Clin Nucl Med"},{"key":"2090_CR64","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1007\/s00259-021-05630-7","volume":"49","author":"R Kuroda","year":"2022","unstructured":"Kuroda R, Wakabayashi H, Araki R, Inaki A, Nishimura R, Ikawa Y, et al. Phase I\/II clinical trial of high-dose [131I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and haematopoietic stem cell transplantation. Eur J Nucl Med Mol Imaging. 2022;49:1574\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2090_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1\u2013133.","journal-title":"Thyroid"},{"key":"2090_CR66","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2967\/jnumed.124.269091","volume":"66","author":"H Weis","year":"2025","unstructured":"Weis H, Weindler J, Schmidt K, Hellmich M, Drzezga A, Schmidt M. Impact of radioactive iodine treatment on long-term relative survival in patients with papillary and follicular thyroid cancer: a SEER-based study covering histologic subtypes and recurrence risk categories. J Nucl Med. 2025;66:525\u201330.","journal-title":"J Nucl Med"},{"key":"2090_CR67","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1007\/s11604-023-01438-7","volume":"41","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhu X, Fan Q, Huang Q, Tu Y, Jiang L, Zhang Z, Chen J. Utility of adjuvant radioactive iodine therapy after reoperation in papillary thyroid carcinoma with cervical lymph node recurrence. Jpn J Radiol. 2023;41:1148\u201356.","journal-title":"Jpn J Radiol"},{"key":"2090_CR68","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11604-023-01517-9","volume":"42","author":"K Watanabe","year":"2024","unstructured":"Watanabe K, Igarashi T, Uchiyama M, Ishigaki T, Ojiri H. Retrospective case-control study examining the relationship between recurrence-free survival and changes in pre- and post-radioiodine therapy serum thyroglobulin levels in patients with differentiated thyroid cancer. Jpn J Radiol. 2024;42:391\u20137.","journal-title":"Jpn J Radiol"},{"key":"2090_CR69","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1007\/s12149-024-01963-z","volume":"38","author":"X Dai","year":"2024","unstructured":"Dai X, Ren X, Zhang J, Zheng Y, Wang Z, Cheng G. Advances in the selection and timing of postoperative radioiodine treatment in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2024;38:688\u201399.","journal-title":"Ann Nucl Med"},{"key":"2090_CR70","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2967\/jnumed.110.081059","volume":"52","author":"T Higashi","year":"2011","unstructured":"Higashi T, Nishii R, Yamada S, Nakamoto Y, Ishizu K, Kawase S, et al. Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med. 2011;52:683\u20139.","journal-title":"J Nucl Med"},{"key":"2090_CR71","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.2967\/jnumed.123.266871","volume":"65","author":"S Resch","year":"2024","unstructured":"Resch S, Ziegler SI, Sheikh G, Unterrainer LM, Zacherl MJ, Bartenstein P, et al. Impact of the reference multiple-time-point dosimetry protocol on the validity of single-time-point dosimetry for [177Lu]Lu-PSMA-I&T therapy. J Nucl Med. 2024;65:1272\u20138.","journal-title":"J Nucl Med"},{"key":"2090_CR72","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1007\/s12149-024-01960-2","volume":"38","author":"W Handayani","year":"2024","unstructured":"Handayani W, Chantadisai M, Phromphao B, Noipinit N, Pasawang P, Khamwan K. Comparative post-therapeutic dosimetry between 2D planar-based and hybrid-based methods for personalized Lu-177 treatment. Ann Nucl Med. 2024;38:884\u201393.","journal-title":"Ann Nucl Med"},{"key":"2090_CR73","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s11604-024-01585-5","volume":"42","author":"T Ono","year":"2024","unstructured":"Ono T, Ichikawa M, Tanada T, Kanezawa C, Sato H. Maximum tumor diameter and renal function can predict the declining surface dose rate after 177Lu-Dotatate: preliminary results of single institution in Japan. Jpn J Radiol. 2024;42:1031\u20137.","journal-title":"Jpn J Radiol"},{"key":"2090_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.675014","volume":"8","author":"N Naskar","year":"2021","unstructured":"Naskar N, Lahiri S. Theranostic terbium radioisotopes: challenges in production for clinical application. Front Med (Lausanne). 2021;8: 675014.","journal-title":"Front Med (Lausanne)"},{"key":"2090_CR75","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3390\/biophysica4040046","volume":"4","author":"CMJ Buchanan","year":"2024","unstructured":"Buchanan CMJ, Aboagye EO, Evitts LJ, Rushton MJD, Smith TAD. Modelling potential candidates for targeted auger therapy. Biophysica. 2024;4:711\u201323.","journal-title":"Biophysica"},{"key":"2090_CR76","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","volume":"46","author":"C M\u00fcller","year":"2019","unstructured":"M\u00fcller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1919\u201330.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2090_CR77","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","volume":"49","author":"F Borgna","year":"2022","unstructured":"Borgna F, Haller S, Rodriguez JMM, Ginj M, Grundler PV, Zeevaart JR, et al. Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2022;49:1113\u201326.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2090_CR78","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2967\/jnumed.122.265291","volume":"64","author":"A Al-Ibraheem","year":"2023","unstructured":"Al-Ibraheem A, Doudeen RM, Juaidi D, Abufara A, Maus S. 161Tb-PSMA radioligand therapy: first-in-humans SPECT\/CT imaging. J Nucl Med. 2023;64:1322\u20133.","journal-title":"J Nucl Med"},{"key":"2090_CR79","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1007\/s00259-024-06641-w","volume":"51","author":"J Fricke","year":"2024","unstructured":"Fricke J, Westerbergh F, McDougall L, Favaretto C, Christ E, Nicolas GP, et al. First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum. Eur J Nucl Med Mol Imaging. 2024;51:2517\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2090_CR80","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941\u20134.","journal-title":"J Nucl Med"},{"key":"2090_CR81","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"issue":"25","key":"2090_CR82","first-page":"00203","volume":"S0923\u20137534","author":"B Tombal","year":"2025","unstructured":"Tombal B, Choudhury A, Saad F, Gallardo E, Soares A, Loriot Y, et al. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial. Ann Oncol. 2025;S0923\u20137534(25):00203.","journal-title":"Ann Oncol"},{"key":"2090_CR83","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.eururo.2024.11.027","volume":"87","author":"S Gillessen","year":"2025","unstructured":"Gillessen S, Tombal B, Turco F, Choudhury A, Rodriguez-Vida A, Gallardo E, et al. Decrease in fracture rate with mandatory bone-protecting agents in the EORTC 1333\/PEACE-3 trial comparing radium-223 combined with enzalutamide versus enzalutamide alone: a safety analysis. Eur Urol. 2025;87:285\u20138.","journal-title":"Eur Urol"},{"key":"2090_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2024.108990","author":"M Tosato","year":"2025","unstructured":"Tosato M, Favaretto C, Kleynhans J, Burgoyne AR, Gestin JF, van der Meulen NP, et al. Alpha Atlas: Mapping global production of \u03b1-emitting radionuclides for targeted alpha therapy. Nucl Med Biol. 2025. https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108990.","journal-title":"Nucl Med Biol"},{"key":"2090_CR85","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2967\/jnumed.122.264043","volume":"64","author":"S Ballal","year":"2023","unstructured":"Ballal S, Yadav MP, Tripathi M, Sahoo RK, Bal C. Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant 225Ac-DOTATATE targeted alpha therapy and capecitabine: a real-world scenario management based long-term outcome study. J Nucl Med. 2023;64:211\u20138.","journal-title":"J Nucl Med"},{"key":"2090_CR86","doi-asserted-by":"publisher","first-page":"840","DOI":"10.2967\/jnumed.121.262017","volume":"63","author":"DY Lee","year":"2022","unstructured":"Lee DY, Kim YI. Effects of 225Ac-labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: a meta-analysis. J Nucl Med. 2022;63:840\u20136.","journal-title":"J Nucl Med"},{"key":"2090_CR87","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25:175\u201383.","journal-title":"Lancet Oncol"},{"key":"2090_CR88","doi-asserted-by":"crossref","unstructured":"Watabe T, Hosono M, Kinuya S, Yamada T, Yanagida S, Namba M, et al. Manual on the proper use of sodium astatide ([211At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition). Ann Nucl Med. 2021;35:753\u2013766.","DOI":"10.1007\/s12149-021-01619-2"},{"key":"2090_CR89","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s00259-024-07017-w","volume":"52","author":"T Watabe","year":"2025","unstructured":"Watabe T, Hatano K, Naka S, Sasaki H, Kamiya T, Shirakami Y, et al. First-in-human SPECT\/CT imaging of [211At]PSMA-5: targeted alpha therapy in a patient with refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52:2253\u20135.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"supplement 1","key":"2090_CR90","volume":"66","author":"T Watabe","year":"2025","unstructured":"Watabe T, Mukai K, Naka S, Sasaki H, Kamiya T, Fukuhara A, et al. J Nucl Med. 2025;66(supplement 1): 251278.","journal-title":"J Nucl Med"},{"key":"2090_CR91","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s10555-021-10011-5","volume":"40","author":"M Takacova","year":"2021","unstructured":"Takacova M, Kajanova I, Kolarcikova M, Lapinova J, Zatovicova M, Pastorekova S. Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX. Cancer Metastasis Rev. 2021;40:1035\u201353.","journal-title":"Cancer Metastasis Rev"},{"key":"2090_CR92","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/jjco\/hyae075","volume":"54","author":"N Nakaigawa","year":"2024","unstructured":"Nakaigawa N, Hasumi H, Utsunomiya D, Yoshida K, Ishiwata Y, Oka T, et al. Evaluation of PET\/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP). Jpn J Clin Oncol. 2024;54:873\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"2090_CR93","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2967\/jnumed.123.267175","volume":"65","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Tran B, Feldman DR, Pokorska-Bocci A, Pichereau S, Wessen J, et al. First-in-human safety, imaging, and dosimetry of a carbonic anhydrase ix-targeting peptide, [68Ga]Ga-DPI-4452, in patients with clear cell renal cell carcinoma. J Nucl Med. 2024;65:740\u20133.","journal-title":"J Nucl Med"},{"key":"2090_CR94","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.3390\/cancers12113328","volume":"12","author":"S Len\u00e1rt","year":"2020","unstructured":"Len\u00e1rt S, Len\u00e1rt P, \u0160marda J, Rem\u0161\u00edk J, Sou\u010dek K, Bene\u0161 P. Trop2: jack of all trades, master of none. Cancers (Basel). 2020;12:3328.","journal-title":"Cancers (Basel)"},{"key":"2090_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200762","volume":"32","author":"Q Liao","year":"2024","unstructured":"Liao Q, Zhang R, Ou Z, Ye Y, Zeng Q, Wang Y, et al. TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs. Mol Ther Oncol. 2024;32: 200762.","journal-title":"Mol Ther Oncol"},{"key":"2090_CR96","doi-asserted-by":"publisher","DOI":"10.1172\/JCI185408","volume":"135","author":"H Chen","year":"2024","unstructured":"Chen H, Zhao L, Pang Y, Shi J, Gao H, Sun Y, et al. 68Ga-MY6349 PET\/CT imaging to assess Trop2 expression in multiple types of cancer. J Clin Invest. 2024;135: e185408.","journal-title":"J Clin Invest"},{"key":"2090_CR97","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41181-023-00235-x","volume":"9","author":"Y Wu","year":"2024","unstructured":"Wu Y, Li T, Zhang X, Jing H, Li F, Huo L. Preclinical evaluation of the theranostic potential of 89Zr\/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model. EJNMMI Radiopharm Chem. 2024;9:5.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"2090_CR98","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s11864-022-00940-w","volume":"23","author":"H Hashimoto","year":"2022","unstructured":"Hashimoto H, Tanaka Y, Murata M, Ito T. Nectin-4: a novel therapeutic target for skin cancers. Curr Treat Options Oncol. 2022;23:578\u201393.","journal-title":"Curr Treat Options Oncol"},{"key":"2090_CR99","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, Matsubara N, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125\u201335.","journal-title":"N Engl J Med"},{"key":"2090_CR100","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","volume":"29","author":"X Duan","year":"2023","unstructured":"Duan X, Xia L, Zhang Z, Ren Y, Pomper MG, Rowe SP, et al. First-in-human study of the radioligand 68GA-N188 targeting Nectin-4 for PET\/CT imaging of advanced urothelial carcinoma. Clin Cancer Res. 2023;29:3395\u2013407.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"2090_CR101","doi-asserted-by":"publisher","first-page":"12S","DOI":"10.2967\/jnumed.123.266830","volume":"65","author":"J Zhang","year":"2024","unstructured":"Zhang J, Duan X, Chen X, Zhang Z, Sun H, Shou J, et al. Translational PET imaging of Nectin-4 expression in multiple different cancers with 68Ga-N188. J Nucl Med. 2024;65(Suppl 1):12S-18S.","journal-title":"J Nucl Med"},{"key":"2090_CR102","doi-asserted-by":"publisher","first-page":"12386","DOI":"10.3390\/ijms252212386","volume":"25","author":"K Kaneda-Nakashima","year":"2024","unstructured":"Kaneda-Nakashima K, Shirakami Y, Hisada K, Feng S, Kadonaga Y, Ooe K, et al. Development of LAT1-selective nuclear medicine therapeutics using astatine-211. Int J Mol Sci. 2024;25:12386.","journal-title":"Int J Mol Sci"},{"key":"2090_CR103","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.2967\/jnumed.123.266313","volume":"64","author":"T Watabe","year":"2023","unstructured":"Watabe T, Kabayama K, Naka S, Yamamoto R, Kaneda K, Serada S, et al. Immuno-PET and targeted \u03b1-therapy using anti-glypican-1 antibody labeled with 89Zr or 211at: a theranostic approach for pancreatic ductal adenocarcinoma. J Nucl Med. 2023;64:1949\u201355.","journal-title":"J Nucl Med"},{"key":"2090_CR104","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1007\/s00259-025-07139-9","volume":"52","author":"T Watabe","year":"2025","unstructured":"Watabe T, Iwasawa T, Kimura H, Shirakami Y, Naka S, Kaneda K, et al. Theranostics using 89Zr\/177Lu-labeled antibody targeting erythropoietin-producing hepatocellular A2 (EphA2). Eur J Nucl Med Mol Imaging. 2025;52:2887\u201397.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02090-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T03:35:40Z","timestamp":1757302540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02090-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,27]]},"references-count":104,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2090"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02090-z","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,27]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}